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SUMMARY 
The effect of Tumor necrosis factor-alpha and testosterone was evaluated on the isolated 
Rana tigrina frog heart. The isolated frog heart (n= 10) were used for this study and the 
effect of drugs on myocardial contractility and heart rate was ascertained. Namely three 
drugs testosterone (4mg), bicalutamide (8mg) and TNF-alpha antagonist infliximab 
(0.4mg) were utilized for this study. Testosterone caused an increase in heart rate by 
11.28% and decrease in myocardial contractility by 17.67%. Similarly bicalutamide caused 
a 20.11% decrease heart rate and 41.17% decrease in myocardial contractility. To ascertain 
the role of TNF-alpha, infliximab was perfused through the heart and it potentiated the 
inhibitory effect of testosterone on the myocardial contractility and heart rate. The results 
of this study suggest the importance of TNF-alpha and testosterone hormone in 
cardiovascular pathophysiology. 
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1. Introduction 
Tumor necrosis factor-alpha (TNF-alpha) 
antagonists have emerged as effective therapy 
for patients with rheumatoid arthritis (RA), 
Crohns disease (CD) and other conditions. 
Early data suggested that they might be a 
promising treatment for heart failure (HF). 
However, randomised controlled trails of TNF-
alpha  antagonists in HF  patients were halted 
due to lack of benefit or trends towards 
worsened HF in patients receiving higher 
TNF-alpha antagonist doses[1]. Testosterone 
depletion (castration) or subcutaneous 
testosterone blockade 4 wk before I/R 
improved cardiac functional recovery and 
decreased myocardial cytokine production, 
inflammatory signalling and expression of 
apoptotic-related proteins[2]. Testosterone is 
the predominant androgenic hormone and has 
a vast range of biological actions.  
The classical effects of testosterone are the 
induction and maintenance of secondary 
sexual characteristics and preservation of 
libido, sense of well-being, lean mass and bone 
density. The hormone is involved in a negative 
biofeedback mechanism on the hypothalamic-
pituitary axis to inhibit gonadotropin secretion. 
It has long been recognized that testosterone 
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has an immune–modulating action. The 
greater incidence of immune-mediated disease 
in women and androgen deficient men has 
attributed to the immunosuppressive effects of 
androgens compared with estrogens [3]. 
Circulating and cardiac TNF-alpha levels are 
elevated in heart diseases such as dilated 
cardiomyopathy, myocardial infraction and 
left ventricular (LV) Pressure overload [4, 5]. A 
high–cholesterol diet and environmental 
tobacco smoke have detrimental effects on 
endothelial function of male animals, effects 
was exacerbated by testosterone at 
physiological concentration (6). 
In 1975, Carswell et al. first identified 
tumor necrosis factor (TNF), an endotoxin-
induced serum factor that caused necrosis of 
tumors [7].A decade later, investigators 
isolated a protein from endotoxin treated cells 
that was named cachectin because of its 
presumed role in the molecular basis of 
cachexia [8]. The subsequent cloning of the 
genes encoding cachectin and TNF alpha 
confirmed that these two molecules were 
identical. Produced as a pro-hormone of 233 
amino acids, TNF-alpha is anchored in the cell 
membrane and then processed to a 157 residue 
mature protein by cleavage of a 76 residue 
signal peptide. In response to a wide variety of 
infectious or inflammatory stimuli (e.g. 
lipopolysaccharide, viruses, fungal or parasitic 
antigens, interleukin-1 (IL-1), TNF alpha), both 
transcription and translation of TNF precursor 
is increased and large amount of mature 
protein are rapidly released in to the 
circulation. However, not all of the TNF-alpha 
is released, as some remains cell –associated in 
a transmembrane form [9]. 
Tumor necrosis factor regulates the 
expression of a variety of peptide regulatory 
factors including IL-1, IL-6, platelet derived 
growth factor, transforming growth factor-beta 
as well as a group of eicosanoids factor and 
adrenaline [10]. It is produced by a host in 
response to stress-infection, inflammation, 
tissue injury and shock and has recently been 
recognized as myocardial depressant 
substance.  
Since the first observation by Levine noting 
increased levels of circulating TNF-alpha 
occurring in patients with severe symptomic 
heart failure, further clinical studies have 
supported the potential importance of TNF-
alpha in the pathogenesis of this disease 
process [11]. In an in-vivo experiment by 
Bozkurt and colleagues, adults were surgically 
implanted with an osmotic minipump and 
infused with TNF-alpha in order to reach 
plasma levels comparable to those reported in 
clinical heart failure. It showed TNF-alpha 
mediated myocyte injury and cell loss which 
may be due to immune-related cytotoxicity. In 
a rat model of TNF-alpha infusion, Bozkurt 
and colleagues observed a small increase in the 
overage LV myocybes-cross sectional area and 
decrease in the calculated number of myocytes 
across the transmural thickness of the LV 
wall[12]. 
Transgenic mice over-expression 
myocardial TNF-alpha demonstrated 
increased soluble myocardial collagen, which 
is suggestive of reduced collagen cross linking 
[13]. Human endothelial cells treated with 
TNF-alpha had increased levels of MMP 
mRNA and demonstrated increased levels of 
MMP activation [14]. Furthermore, human 
smooth muscle cells stimulated with TNF-
alpha demonstrated increased MMP activity 
and de novo synthesis and secretion of MMP-
1[15] Adult rat cardiac fibroblasts stimulated 
with TNF-alpha have demonstrated increased 
MMP activity [16]. 
  Laboratory studies using animals with 
experimentally induced inflammatory disease 
have reported a beneficial result with 
testosterone [17].  Moreover, there are small 
clinical trials of testosterone therapy in 
humans with rheumatoid arthritis in which 
major improvements of clinical status and 
inflammatory markers have been recorded [18]. 
Laboratory evidence has suggested that 
testosterone suppresses pro-inflammatory 
cytokines and may up-regulate anti-
inflammatory cytokines. Testosterone 
incubated in cell culture attenuates the 
production of inflammatory cytokines such as 
TNF-alpha, IL-1beta, and IL-6 in human 
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macrophages [19], human monocytes [20], 
human gingival fibroblasts [21] murine and 
human osteoblasts [22,23] and human 
endothelial cells [24]. Furthermore, anti-
inflammatory cytokines such as IL-10 are 
stimulated in the presence of testosterone [25, 
26]. Injection of bacterial endotoxin into 
castrated male mice increased the endogenous 
production of TNF-alpha, which was 
abrogated by testosterone replacement [27]. 
Elderly men with hypogonadism induced with 
gonadotropin hormone-releasing agonists 
developed significant increases in serum TNF-
alpha and IL-6 [28]. Testosterone replacement 
induced reductions in TNF-alpha and IL-1beta 
and an increase in IL-10 with positive co-
relation in hypogonadal male [29] 
It has been demonstrated that pro-
inflammatory cytokines, such as TNF-alpha 
and IL-1beta, have an inhibitory role in 
gonadal functions, especially on the 
steroidogenesis in leydig cells. Elevated TNF-
alpha and IL-1 levels have been measured in 
human patients with critical illness, CHF,  
burns, and sepsis [30,31, 32], who also 
experience depressed gonadal functions with 
low serum testosterone levels [33,34]. 
Administration of TNF-alpha to healthy men 
and rats also causes a decrease in serum 
testosterone levels [35,36] while treatment with 
TNF-alpha or IL-1 causes an inhibition of 
steroidogenesis in cultured leydig cells. Pro-
inflammatory cytokines TNF-alpha, IL-1, and 
IL-6 inhibit testicular leydig cell 
steroidogenesis at the level of gene expression 
of different steroidogenic enzymes [37]. 
Steroidogenesis in leydig cells is started 
with cholesterol transfer into the mitochondria, 
mediated by the steroidogenic acute regulatory 
(STAR) protein. Cholesterol is converted to 
pregnenolone by the cholesterol side chain 
cleavage enzyme (P450scc) in the mitochondria. 
Pregnenolone is then converted sequentially to 
progesterone by 3beta-hydroxysteroid 
dehydrogenase (3ß-HSD), to 17alpha-
hydoxyprogesterone and then to 
androstenedione by 17alpha-hydroxylase 
(P450c17), and finally to testosterone by 
17beta- hydroxyateroid dehydrogenase. 
Steroidogenesis in leydig cells is primarily 
regulated by the pituitary gonadotropin, 
luteinizing hormone (LH) through the 
production of the intracellular second 
messenger cyclic AMP (cAMP) which 
stimulates steroidogenesis by increasing the 
expression of steroidogenic-enzyme genes[38] 
Nur77, which is also known as NGFI-B, TR3, 
and NAK-1, is a member of the Nur77 gene 
family. These factors are highly homologous in 
the zinc finger DNA-binding domain, 
moderately homologous in the ligand-binding 
domain, and somewhat divergent in the N 
terminus[39]NF- B is also able to repress the 
activities of other transcription factors, such as 
steroid receptors[40].  
2. Materials and Methods 
Materials Testosterone enanthate injections 
were purchased from German Remedies, 
Mumbai. Infliximab recombinant, Remicade 
were purchased from Fulford India Limited, a 
subsidiary of Schering-Plough Corporation, 
Mumbai, India. Bicalutamide injections were 
purchased from Intas Pharmaceuticals Ltd., 
Matoda, Ahmedabad, India. All other reagents 
and chemicals were of analytical grade.  
 
Kymograph Starlings Heart lever and 
Kymograph (Inco, Ambala, India) were used 
to record the responses of testosterone, 
bicalutamide and infliximab on suited 
kymograph papers. 
 
Physiological solution: Frogs Ringer 
solution was used as a perfusion solution to 
maintain the rhythm of the isolated tissue. The 
composition of Ringer solution includes NaCl 
(6.5g/ L), NaHCO3 (0.2g/ L), KCl (0.14 g/L), 
NaH2Po4 (0.01 g/L), Dextrose (2.0 g/L) and 
Cacl2 (0.12 g/L). This frog ringer reagent was 
diluted with one liter of distilled water and 
adjusted to pH of 7.3. 
 
Isolated Frog Heart Preparation Using Symes 
Technique: 
 
Isolation of frog heart was done by 
standard procedure (41). Briefly, an Indian 
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frog (Rana tigrina) was stunned after ether 
anesthesia and abdomen was cut and opened. 
The pectoral girdle was cut using a bone cutter 
and pericardium was removed carefully. 
Syme’s cannula was connected to the reservoir 
containing frog Ringers solution and 
introduced immediately into the Sinus venosus 
of the frog’s heart. The connecting blood 
vessels were cut and heart was isolated from 
the animal and mounted on to a stand. Heart 
was connected to the Starling’s heart lever and 
adjusted for recording the responses of the 
heart. The level of frog Ringer solution in the 
Syme’s cannula was maintained by fixing a 
glass tube into the cork fixed to the reservoir 
(Marriott’s bottle) tightly. The heart was 
allowed to stabilize for 30 minutes before 
measurement of heart rate and cardiac output. 
The recordings were made on a slow rotating 
drum, to which a suited kymograph paper was 
affixed.  
Procedure: 
Initially, Frog Ringer solution was 
perfused in to the isolated frog heart and the 
results of heart contraction and heart rate was 
noted. This first frog ringer solution indicating 
results is normal control values. 
 
First time the testosterone (it’s called 
Testosterone 1) was per fused in to the frog 
heart and the results of heart contractility and 
heart rate was predicted. 
 
After perfusion of testosterone 1, we 
waited for 10 minutes to get baseline, 
meanwhile the frog ringer solution was 
perfused. 
 
Likewise bicaluatamide, testosterone 2, 
ringer 2, infliximab and testosterone 3 were 
per fused periodically in to frog heart and the 
results of heart contractility and heart was 
noted. 
The Effect of testosterone was studied by 
perfusing frog Ringer solution containing 
testosterone, bicalutamide, infliximab solution 
to the isolated frog heart preparation. This test 
solution was perfused in to the heart 
periodically (10 minutes for each drug). The 
parameters studied included force of 
contraction and heart rate (n=10). Then this 
parameter was compared with control frog 
ringer solution.  
 
Statistical Analysis 
Statistical analysis of parameters of cardiac 
rate and myocardial contractility were 
performed by using of Wilcoxon signed Ranks 
test. Values were expressed as mean ± SEM 
with values of p<0.05 considered significant. 
 
3. Results       
 
Table: 1. Effects of Testosterone, Bicalutamide, 
Infliximab on frog heart 
 
According to results shown in table, 
testosterone showed increase in heart rate by 
11.28% and reduction in myocardial 
contractility by 17.67% which was significant. 
Effect of bicalutamide on testosterone induced 
cardiac effects was not significant. But 
bicalutamide itself has produced reduction in 
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Exp. 
Heart 
Rate(Beats/min) 
Myocardial  
Contractility(Amp. 
of contraction) 
Ringer 100 100 
Testosterone 
1 111.28 + 9.42 83.33+15.72 
Bicalutamide 79.89+6.46 58.83+10.78 
Testosterone 
2 92.49+2.74 93+10.64 
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both heart rate and myocardial contractility 
which was significant statistically. 
 
 
Figure 1: Heart Rate; Infliximab on Testosterone. 
 
 
 
 
 
 
 
 
 
 
 
 
In the figure 1 indicates the effect of Infliximab 
on testosterone  in the  heart .In this study the 
infliximab act as a crucial role,it reduce the heart 
rate of testosterone treated heart .The ‘p’ value is 
less than.0.05 (p<.005). 
 
Figure 2: Myocardial Contractility; Infliximab on 
Testosterone. 
 
 
 
 
 
 
 
 
 
 
 
In the figure 2 indicates the effect of 
Infliximab on testosterone in the heart. The 
Infliximab decrease the myocardial 
contractility of testosterone treated heart. The 
‘p’ value is less than 0.05 (p<0.007).  
 
The ‘p’ values of cardiac rate and 
myocardial contractility of infliximab and 
testosterone is ‘significant’. 
 
4. Discussion 
 
The main findings of the present study has 
suggests that the anti-tumor necrosis factor 
drug, infliximab potentiates the inhibitory 
effect of testosterone on the myocardial 
contractility and heart rate.  
Cardiovascular disease shows a consistent 
male to female ratio of 2.2 among different 
population despite wide variation in absolute 
rates. Most studies have focused on the role of 
estrogen in cardiac protection, whereas there is 
less data which exist regarding the effect of 
testosterone in cardiac injury and it may be 
important because the heart can accumulate 
testosterone at higher concentration than other 
androgen target organs [42]and functional 
androgen receptors are present in isolated 
cardiac myocytes [43]. A vast number of 
studies have been done to show association 
between low testosterone and cardiovascular 
disease or its risk factors. In rats, androgen 
therapy improves coronary blood flow and 
increases both fractional shortening and peak 
myocardial oxygen consumption, thereby 
improving cardiac function[44].Testosterone 
therapy has been used to treat men with 
angina; the beneficial effects on both ischemia 
and exercise tolerance have been demonstrated 
in several studies. Numerous reports from 
animal studies have demonstrated the 
vasodilator properties of androgens in several 
vascular beds, both in vitro and in vivo.  In 
humans, testosterone reduces blood pressure 
and enhances relaxation of brachial arteries; 
direct injection into coronary arteries produces 
dilatation and increased coronary blood flow 
[45-47]. These vasodilatory actions of 
testosterone observed at supra-physiologic 
doses are endothelium and androgen receptor 
independent, and to be mediated via 
membrane ion channels of smooth muscle, 
where low-dose testosterone may be acting via 
endothelium dependant release of vasoactive 
substance like nitric oxide. TNF-alpha is pro-
inflammatory cytokine and is increased in 
infective and inflammatory disease. 
Atherosclerosis is acknowledged to be a 
disease of chronic inflammation.  TNF-alpha is 
both a marker and a mediator of 
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atherosclerotic plaque development and 
complications.  Serum TNF alpha is greatly 
increased during acute coronary syndromes 
but is also increased to a lesser degree in stable 
chronic angina and is a marker of future 
events[48].There are no clinical trial data 
concerning the effects of testosterone on left 
ventricular function. TNF is produced mainly 
by macrophages, but also by the myocardium 
in CHF. It impairs synthesis and promotes 
catabolism of skeletal muscle, and reduces 
testosterone production. It causes endothelial 
dysfunction and impairs production of NO by 
endothelium [49]. Administration causes left 
ventricular dysfunction and heart failure in 
humans; anti-TNF therapy may improve 
cardiac function[50]. 
In this study, we have suggested that the 
increased concentration of testosterone can 
cause severe cardiovascular problems. The 
expression of testosterone was inhibited by 
TNF-α antagonist. Testosterone showed 
increase in cardiac rate and decrease in 
myocardial contractility. These results may 
cause cardiovascular problems or can worsen 
pre-existing heart condition. Bicalutamide was 
not able to reverse the testosterone induced 
cardiac effects as results were insignificant 
(data not shown here). So, testosterone might 
be acting via some different pathway other 
than through androgen receptors. On other 
hand, increased heart rate due to testosterone 
was minimized by TNF-α antagonism with 
infiliximab with statistical significance. So 
TNF-α antagonism with infiliximab might 
interfere with multiple pathways known to 
impair endothelial cell function. 
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